Login to Your Account


TIL kingdom comes? Data with Oncosec's approach lifting hope in melanoma

By Randy Osborne
Staff Writer

Thursday, April 21, 2016

Positive data with Oncosec Medical Inc.'s Immunopulse interleukin-12 (IL-12) electroporation therapy against melanoma "set pulses racing," in the words of H.C. Wainwright analyst Mark Breidenbach, as investors cheered evidence that the approach could boost CD8+ tumor-infiltrating lymphocytes (TILs) and thereby set patients up to benefit more from anti-PD-1/PD-L1 therapy, the emerging standard of care in the deadly skin cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription